CDEX Names New Chief Executive Officer

New CEO James Griffin to lead company's growth strategy in the healthcare, homeland security, law enforcement, and brand protection markets


Under griffin's leadership, CDEX will begin implementation of its growth strategy that includes enlarging the company's intellectual property portfolio, expanding research and development capabilities, accelerating the development and launch of new products, expansion of sales channels, entering selected international markets, setting up strategic business alliances for product development, manufacturing, and service and raising capital for the acquisition of new technologies.

"Jim Griffin's vision and growth strategy for CDEX is fully supported by the CDEX Board of Directors," said Malcolm Philips, Chairman of the CDEX Board. "We have been pleased to have Jim at CDEX as our COO, and look forward to his leadership as CEO."

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona.